ArticleIranian journal of basic medical sciences2026
Resveratrol mitigates diazinon-induced neurotoxicity during fetal brain development.
Article in Iranian journal of basic medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Disruption of transcriptional programs governing fetal neurogenesis represents a critical but underexplored mechanism of diazinon (DZN)-induced developmental neurotoxicity. This research examines whether resveratrol (RV) influences the expression of genes associated with neurogenesis and survival after prenatal exposure to DZN. Materials and Methods: Twenty-four pregnant Wistar rats were divided into DZN (40 mg/kg) group, RV (10 mg/kg), DZN+RV (40 mg/kg + 10 mg/kg), and Control. On day 21 of pregnancy, rats were cesarean sectioned, and the neonatal brains were examined using HPLC, GC-MS, real-time PCR, and histology techniques to assess RV's neuroprotective effects against DZN-induced toxicity. Data were statistically analyzed using SPSS and GraphPad Prism. Results: DZN significantly reduced neuronal survival and altered gene expression in fetal brains, with lower Ptf1α, SOX2, BDNF, and BCL2 levels and higher BAX levels compared to controls. The simultaneous administration of RV partially restored these molecular changes. Histological findings indicated that RV mitigated neuronal damage associated with DZN, resulting in decreased dark neuron formation and preserved myelin integrity in the hippocampus and thalamus. Conclusion: Collectively, these findings suggest that DZN exposure correlates with changes in the molecular and structural composition of the fetal brain, and that RV may help regulate these effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.